USD 156.39
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| GKOS | -0.1 | 0.1 | 6.9 | 21.0 | 26.0 | 75.0 | 201.6 | 172.7 | 400.9 | 400.9 |
| S&P 500 | 1.0 | 1.8 | -0.9 | 2.7 | 7.3 | 26.5 | 31.0 | 80.1 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | GKOS |
| name | Glaukos Corporation |
| price | 156.39 |
| changes percentage | -0.0767 |
| change | -0.12 |
| day low | 153.675 |
| day high | 157.83 |
| year high | 161.13 |
| year low | 83.9 |
| market cap | 8622937986 |
| price avg 50 | 144.3746 |
| price avg 200 | 124.54905 |
| exchange | NYSE |
| volume | 466282 |
| avg volume | 589726 |
| open | 157.24 |
| previous close | 156.51 |
| eps | -3.07 |
| pe | -50.94 |
| earnings announcement | 2025-02-19T10:59:00.000+0000 |
| shares outstanding | 55137400 |
| timestamp | 2025-01-17 21:00:02 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001192448 | |||
| revenue | 314711000 | 282862000 | 11.26 |
| gross profit | 239136000 | 213883000 | 11.81 |
| gross profit ratio | 0.76 | 0.76 | 0.49 |
| research and development expenses | 138768000 | 123271000 | 12.57 |
| operating expenses | 367835999 | 316196000 | 16.33 |
| interest income | 9164000 | 2375000 | 285.85 |
| interest expense | 13633000 | 13720000 | -0.63 |
| ebitda | -82116000 | -48763000 | -68.40 |
| ebitdaratio | -0.26 | -0.37 | 29.51 |
| operating income | -128700000 | -102313000 | -25.79 |
| operating income ratio | -0.41 | -0.36 | -13.06 |
| net income | -134661000 | -99195000 | -35.75 |
| net income ratio | -0.43 | -0.35 | -22.02 |
| eps | -2.78 | -2.09 | -33.01 |
Revenue Growth: revenue increased to 315 million in 2023 from 283 million in 2022 representing a change of 11.26%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 239 million in 2023 from 214 million in 2022 representing a change of 11.81%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 139 million in 2023 from 123 million in 2022 representing a change of 12.57%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -82 million in 2023 from -49 million in 2022 representing a change of -68.4%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -129 million in 2023 from -102 million in 2022 representing a change of -25.79%. The increase in operating income indicates better operational performance and increased profitability.
Operating Expenses: Operating Expenses increased to 368 million in 2023 from 316 million in 2022 representing a change of 16.33%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Net Income: Net income decreased to -135 million in 2023 from -99 million in 2022 representing a change of -35.75%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -2.78 in 2023 from -2.78 in 2022 representing a change of -33.01%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001192448 | |||
| revenue | 96670000 | 95690000 | 1.02 |
| gross profit | 74086000 | 73140000 | 1.29 |
| gross profit ratio | 0.77 | 0.76 | 0.27 |
| research and development expenses | 34746000 | 34426000 | 0.93 |
| operating expenses | 98746000 | 100614000 | -1.86 |
| interest income | 2700000 | 2828000 | -4.53 |
| interest expense | 1663000 | 3355000 | -50.43 |
| ebitda | -10570000 | -29974000 | 64.74 |
| ebitdaratio | -0.11 | -0.2 | 46.47 |
| operating income | -24660000 | -27474000 | 10.24 |
| operating income ratio | -0.26 | -0.29 | 11.15 |
| net income | -21409000 | -50545000 | 57.64 |
| net income ratio | -0.22 | -0.53 | 58.07 |
| eps | -0.39 | -1 | 61.00 |
Revenue Growth: revenue increased to 97 million in 2024Q3 from 96 million in 2024Q2 representing a change of 1.02%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 74 million in 2024Q3 from 73 million in 2024Q2 representing a change of 1.29%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 35 million in 2024Q3 from 34 million in 2024Q2 representing a change of 0.93%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Earnings per Share (EPS): EPS increased to -0.39 in 2024Q3 from -0.39 in 2024Q2 representing a change of 61.0%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 99 million in 2024Q3 from 101 million in 2024Q2 representing a change of -1.86%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -11 million in 2024Q3 from -30 million in 2024Q2 representing a change of 64.74%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -25 million in 2024Q3 from -27 million in 2024Q2 representing a change of 10.24%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -21 million in 2024Q3 from -51 million in 2024Q2 representing a change of 57.64%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001192448 | |||
| total assets | 940414000 | 1002383000 | -6.18 |
| total liabilities | 478648000 | 472378000 | 1.33 |
| total equity | 461766000 | 530005000 | -12.88 |
| cash and cash equivalents | 93467000 | 119525000 | -21.80 |
| short term investments | 201964000 | 233170000 | -13.38 |
| long term investments | 0 | 7078000 | -100.00 |
| total current assets | 395461000 | 443859000 | -10.90 |
| total non current assets | 544953000 | 558524000 | -2.43 |
| total current liabilities | 74014000 | 72359000 | 2.29 |
| total non current liabilities | 404634000 | 400019000 | 1.15 |
| common stock | 49000 | 48000 | 2.08 |
| retained earnings | -599067000 | -464406000 | -29.00 |
| total debt | 383738000 | 382477000 | 0.33 |
Total Assets: Total Assets decreased to 940 million in 2023 from 1,002 million in 2022 representing a change of -6.18%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 479 million in 2023 from 472 million in 2022 representing a change of 1.33%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 462 million in 2023 from 530 million in 2022 representing a change of -12.88%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 93 million in 2023 from 120 million in 2022 representing a change of -21.8%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 202 million in 2023 from 233 million in 2022 representing a change of -13.38%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 395 million in 2023 from 444 million in 2022 representing a change of -10.9%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 74 million in 2023 from 72 million in 2022 representing a change of 2.29%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -599 million in 2023 from -464 million in 2022 representing a change of -29.0%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 384 million in 2023 from 382 million in 2022 representing a change of 0.33%. This indicates an increase in overall debt burden.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 2.08%. This indicates an increase in ownership interest.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001192448 | |||
| total assets | 926543000 | 919675000 | 0.75 |
| total liabilities | 258034000 | 254516000 | 1.38 |
| total equity | 668509000 | 665159000 | 0.50 |
| cash and cash equivalents | 100143000 | 68075000 | 47.11 |
| short term investments | 162330000 | 193589000 | -16.15 |
| long term investments | 0 | 18404000 | -100.00 |
| total current assets | 397282000 | 383781000 | 3.52 |
| total non current assets | 529261000 | 535894000 | -1.24 |
| total current liabilities | 71684000 | 70083000 | 2.28 |
| total non current liabilities | 186350000 | 184433000 | 1.04 |
| common stock | 55000 | 55000 | 0.00 |
| retained earnings | -711859000 | -690450000 | -3.10 |
| total debt | 157127000 | 156613000 | 0.33 |
Total Assets: Total Assets increased to 927 million in 2024Q3 from 920 million in 2024Q2 representing a change of 0.75%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 669 million in 2024Q3 from 665 million in 2024Q2 representing a change of 0.5%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 100 million in 2024Q3 from 68 million in 2024Q2 representing a change of 47.11%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 397 million in 2024Q3 from 384 million in 2024Q2 representing a change of 3.52%. This indicates a better liquidity position.
Total Liabilities: Total Liabilities increased to 258 million in 2024Q3 from 255 million in 2024Q2 representing a change of 1.38%. This indicates an increase in overall liabilities.
Short Term Investments: Short Term Investments decreased to 162 million in 2024Q3 from 194 million in 2024Q2 representing a change of -16.15%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 72 million in 2024Q3 from 70 million in 2024Q2 representing a change of 2.28%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -712 million in 2024Q3 from -690 million in 2024Q2 representing a change of -3.1%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 157 million in 2024Q3 from 157 million in 2024Q2 representing a change of 0.33%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001192448 | |||
| net change in cash | -27280000 | 16479000 | -265.54 |
| operating cash flow | -57758000 | -33083000 | -74.59 |
| free cash flow | -78006000 | -63348000 | -23.14 |
| capital expenditure | -20248000 | -30265000 | 33.10 |
| depreciation and amortization | 37978000 | 35946000 | 5.65 |
| deferred income tax | -120000 | -54000 | -122.22 |
| stock based compensation | 43528000 | 38561000 | 12.88 |
| accounts payables | 0 | 3797000 | -100.00 |
| inventory | 0 | -15472000 | 100.00 |
| acquisitions net | 0 | 151000 | -100.00 |
| investments in property plant and equipment | -20248000 | -30265000 | 33.10 |
| net cash used for investing activites | 14095000 | 44779000 | -68.52 |
| debt repayment | -711000 | -527000 | -34.91 |
| common stock issued | 0 | 9207000 | -100.00 |
| common stock repurchased | -3273000 | -2730000 | -19.89 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 15042000 | 6251000 | 140.63 |
| cash at end of period | 99323000 | 126603000 | -21.55 |
| accounts receivables | 0 | -3138000 | 100.00 |
| cash at beginning of period | 126603000 | 110124000 | 14.96 |
Net Change in Cash: Net Change in Cash decreased to -27 million in 2023 from 16 million in 2022 representing a change of -265.54%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -58 million in 2023 from -33 million in 2022 representing a change of -74.59%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -78 million in 2023 from -63 million in 2022 representing a change of -23.14%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to -20 million in 2023 from -30 million in 2022 representing a change of 33.1%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 44 million in 2023 from 39 million in 2022 representing a change of 12.88%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Receivables: Accounts Receivables increased to 0 in 2023 from -3 million in 2022 representing a change of 100.0%. This suggests that the company is less capable of collecting payments from its customers.
Accounts Payables: The absolute value of Accounts Payables decreased to 0 million in 2023 from 4 million in 2022 representing a change of -100.0%. This indicates that the company has reduced its outstanding obligations to its suppliers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001192448 | |||
| operating cash flow | -9586000 | -18369000 | 47.81 |
| free cash flow | -11036000 | -20518000 | 46.21 |
| capital expenditure | -1450000 | -2149000 | 32.53 |
| depreciation and amortization | 8999000 | 7927000 | 13.52 |
| deferred income tax | 1000 | -2000 | 150.00 |
| stock based compensation | 14420000 | 11313000 | 27.46 |
| accounts receivables | -4462000 | -4908000 | 9.09 |
| accounts payables | 565000 | -1351000 | 141.82 |
| inventory | -3056000 | -6554000 | 53.37 |
| acquisitions net | -38000 | 38000 | -200.00 |
| investments in property plant and equipment | -1450000 | -2149000 | 32.53 |
| net cash used for investing activites | 30563000 | 34864000 | -12.34 |
| debt repayment | -242000 | -226000 | -7.08 |
| common stock issued | 199989000 | 0 | NaN |
| common stock repurchased | 2127000 | -2127000 | 200.00 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 9668000 | 8592000 | 12.52 |
| net change in cash | 36801000 | 25580000 | 43.87 |
| cash at end of period | 104876000 | 68075000 | 54.06 |
| cash at beginning of period | 68075000 | 42495000 | 60.20 |
Net Change in Cash: Net Change in Cash increased to 37 million in 2024Q3 from 26 million in 2024Q2 representing a change of 43.87%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -10 million in 2024Q3 from -18 million in 2024Q2 representing a change of 47.81%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -11 million in 2024Q3 from -21 million in 2024Q2 representing a change of 46.21%. This indicates an increase in cash generated after accounting for capital expenditures.
Accounts Payables: The absolute value of Accounts Payables decreased to 1 million in 2024Q3 from 1 million in 2024Q2 representing a change of 141.82%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure increased to -1 million in 2024Q3 from -2 million in 2024Q2 representing a change of 32.53%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Deferred Income Tax: Deferred Income Tax increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 150.0%. This indicates that the company's tax liability for future periods has increased.
Stock-Based Compensation: Stock-Based Compensation increased to 14 million in 2024Q3 from 11 million in 2024Q2 representing a change of 27.46%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Receivables: Accounts Receivables increased to -4 in 2024Q3 from -5 million in 2024Q2 representing a change of 9.09%. This suggests that the company is less capable of collecting payments from its customers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 6.5 | 5.96 | 8.99 |
| net income per share | -2.78 | -2.09 | -32.98 |
| operating cash flow per share | -1.19 | -0.7 | -71.02 |
| free cash flow per share | -1.61 | -1.34 | -20.62 |
| cash per share | 6.1 | 7.43 | -17.95 |
| book value per share | 9.53 | 11.17 | -14.65 |
| tangible book value per share | 2.33 | 3.29 | -29.25 |
| shareholders equity per share | 9.53 | 11.17 | -14.65 |
| interest debt per share | 8.2 | 8.35 | -1.75 |
| market cap | 3849939170.0 | 2072353920 | 85.78 |
| enterprise value | 4140210170.0 | 2335305920 | 77.29 |
| pe ratio | -28.59 | -20.89 | -36.85 |
| price to sales ratio | 12.23 | 7.33 | 66.98 |
| pocfratio | -66.66 | -62.64 | -6.41 |
| pfcf ratio | -49.35 | -32.71 | -50.87 |
| pb ratio | 8.34 | 3.91 | 113.23 |
| ptb ratio | 8.34 | 3.91 | 113.23 |
| ev to sales | 13.16 | 8.26 | 59.35 |
| enterprise value over ebitda | -50.42 | -47.89 | -5.28 |
| ev to operating cash flow | -71.68 | -70.59 | -1.55 |
| ev to free cash flow | -53.08 | -36.86 | -43.97 |
| earnings yield | -0.03 | -0.05 | 26.93 |
| free cash flow yield | -0.02 | -0.03 | 33.72 |
| debt to equity | 0.83 | 0.72 | 15.16 |
| debt to assets | 0.41 | 0.38 | 6.94 |
| net debt to ebitda | -3.53 | -5.39 | 34.45 |
| current ratio | 5.34 | 6.13 | -12.90 |
| interest coverage | -9.44 | -7.46 | -26.59 |
| income quality | 0.43 | 0.33 | 28.60 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.71 | 0.67 | 5.05 |
| research and ddevelopement to revenue | 0.44 | 0.44 | 1.18 |
| intangibles to total assets | 0.37 | 0.37 | -0.51 |
| capex to operating cash flow | -0.35 | -0.91 | 61.68 |
| capex to revenue | 0.06 | 0.11 | -39.87 |
| capex to depreciation | 0.53 | 0.84 | -36.68 |
| stock based compensation to revenue | 0.14 | 0.14 | 1.46 |
| graham number | 24.42 | 22.92 | 6.53 |
| roic | -0.15 | -0.11 | -34.98 |
| return on tangible assets | -0.23 | -0.16 | -44.26 |
| graham net net | -2.73 | -1.55 | -75.88 |
| working capital | 321447000 | 371500000 | -13.47 |
| tangible asset value | 112676000 | 156002000 | -27.77 |
| net current asset value | -83187000 | -28519000 | -191.69 |
| invested capital | 845075000 | 912333000 | -7.37 |
| average receivables | 37961500 | 34755500 | 9.22 |
| average payables | 13921500 | 10868000 | 28.10 |
| average inventory | 39913500 | 30426000 | 31.18 |
| days sales outstanding | 46.22 | 46.55 | -0.71 |
| days payables outstanding | 64.91 | 76.21 | -14.83 |
| days of inventory on hand | 202.78 | 200.23 | 1.27 |
| receivables turnover | 7.9 | 7.84 | 0.71 |
| payables turnover | 5.62 | 4.79 | 17.41 |
| inventory turnover | 1.8 | 1.82 | -1.25 |
| roe | -0.29 | -0.19 | -55.82 |
| capex per share | 0.42 | 0.64 | -34.46 |
ROE: Return on Equity (ROE) decreased to -0.29 on 2023-12-31 from -0.19 on 2022-12-31, representing a change of -55.82%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -28.59 on 2023-12-31 from -20.89 on 2022-12-31, representing a change of -36.85%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 5.34 on 2023-12-31 from 6.13 on 2022-12-31, representing a change of -12.90%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.83 on 2023-12-31 from 0.72 on 2022-12-31, representing a change of 15.16%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| GKOS | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 1.76 | 1.89 | -6.91 |
| net income per share | -0.39 | -1.0 | 60.97 |
| operating cash flow per share | -0.17 | -0.36 | 51.91 |
| free cash flow per share | -0.2 | -0.4 | 50.44 |
| cash per share | 4.77 | 5.16 | -7.57 |
| book value per share | 12.15 | 13.12 | -7.39 |
| tangible book value per share | 6.05 | 6.38 | -5.12 |
| shareholders equity per share | 12.15 | 13.12 | -7.39 |
| interest debt per share | 2.89 | 3.15 | -8.53 |
| market cap | 7170220360 | 5954955300 | 20.41 |
| enterprise value | 7227204360 | 6043493300 | 19.59 |
| pe ratio | -83.73 | -29.45 | -184.27 |
| price to sales ratio | 74.17 | 62.23 | 19.19 |
| pocfratio | -747.99 | -324.19 | -130.73 |
| pfcf ratio | -649.71 | -290.23 | -123.86 |
| pb ratio | 10.73 | 8.95 | 19.80 |
| ptb ratio | 10.73 | 8.95 | 19.80 |
| ev to sales | 74.76 | 63.16 | 18.37 |
| enterprise value over ebitda | -683.75 | -201.62 | -239.12 |
| ev to operating cash flow | -753.93 | -329.01 | -129.16 |
| ev to free cash flow | -654.88 | -294.55 | -122.33 |
| earnings yield | -0.0 | -0.01 | 64.82 |
| free cash flow yield | -0.0 | -0.0 | 55.33 |
| debt to equity | 0.24 | 0.24 | -0.17 |
| debt to assets | 0.17 | 0.17 | -0.42 |
| net debt to ebitda | -5.39 | -2.95 | -82.51 |
| current ratio | 5.54 | 5.48 | 1.21 |
| interest coverage | -14.83 | -8.19 | -81.08 |
| income quality | 0.45 | 0.36 | 23.21 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.36 | 0.36 | -0.09 |
| intangibles to total assets | 0.36 | 0.37 | -2.56 |
| capex to operating cash flow | -0.15 | -0.12 | -29.29 |
| capex to revenue | 0.01 | 0.02 | -33.21 |
| capex to depreciation | 0.16 | 0.27 | -40.56 |
| stock based compensation to revenue | 0.15 | 0.12 | 26.17 |
| graham number | 10.31 | 17.15 | -39.88 |
| roic | -0.03 | -0.03 | 10.40 |
| return on tangible assets | -0.04 | -0.09 | 58.58 |
| graham net net | 1.39 | 1.46 | -4.24 |
| working capital | 325598000 | 313698000 | 3.79 |
| tangible asset value | 332957000 | 323352000 | 2.97 |
| net current asset value | 139248000 | 129265000 | 7.72 |
| invested capital | 829417000 | 825135000 | 0.52 |
| average receivables | 53812500 | 48881000 | 10.09 |
| average payables | 11331500 | 12156000 | -6.78 |
| average inventory | 58187500 | 53332500 | 9.10 |
| days sales outstanding | 52.52 | 48.17 | 9.02 |
| days payables outstanding | 44.25 | 46.14 | -4.10 |
| days of inventory on hand | 238.69 | 225.42 | 5.89 |
| receivables turnover | 1.71 | 1.87 | -8.27 |
| payables turnover | 2.03 | 1.95 | 4.27 |
| inventory turnover | 0.38 | 0.4 | -5.56 |
| roe | -0.03 | -0.08 | 57.86 |
| capex per share | 0.03 | 0.04 | -37.83 |
ROE: Return on Equity (ROE) increased to -0.03 on 2024-09-30 Q3 from -0.08 on 2024-06-30 Q2, representing a change of 57.86%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -83.73 on 2024-09-30 Q3 from -29.45 on 2024-06-30 Q2, representing a change of -184.27%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 5.54 on 2024-09-30 Q3 from 5.48 on 2024-06-30 Q2, representing a change of 1.21%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.24 on 2024-09-30 Q3 from 0.24 on 2024-06-30 Q2, representing a change of -0.17%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is -23.49 which is lower than current price 156.39, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-15 09:55:25
Glaukos' iDose TR achieves lasting IOP reduction and safety, transforming glaucoma treatment. The company is progressing well with its next-generation iDose TREX.
Sentiment: Positive
Publish Date: 2025-01-14 16:05:00
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced several positive clinical updates for its iDose® sustained-release procedural pharmaceutical platform, including: In a new 36-month follow-up analysis of its two Phase 3 pivotal clinical trials, iDose TR (travoprost intracameral implant) 75 mcg, an FDA-.
Sentiment: Positive
Publish Date: 2025-01-09 08:56:21
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Sentiment: Positive
Publish Date: 2025-01-07 12:57:20
Investors are optimistic about GKOS' strength in its product portfolio amid robust demand and expansion in new markets.
Sentiment: Positive
Publish Date: 2024-12-31 08:59:29
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Sentiment: Neutral
Publish Date: 2024-12-24 13:41:11
GKOS announces New Drug Application submission for its Epioxa to the FDA.
Sentiment: Positive
Publish Date: 2024-12-23 07:00:00
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Epioxa™ (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, a progressive, sight-threatening corneal dise.
Sentiment: Positive
Publish Date: 2024-12-21 07:04:19
Glaukos Corporation (GKOS) is well-positioned to grow sales at a CAGR of ~20% to FY'27, potentially hitting $680mm in revenues and $90-$100mm post-tax earnings. The stock is currently valued at 21x sales, with high expectations for future growth, but a 27% margin of safety exists at current prices. GKOS's efficient asset base and strong cash conversion support sustainable growth, driven by iDose TR and iStent infinite uptake in domestic and international markets.
Sentiment: Neutral
Publish Date: 2024-12-12 03:16:11
Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog.
Sentiment: Positive
Publish Date: 2024-12-11 09:36:08
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Sentiment: Positive
Publish Date: 2024-12-11 08:55:37
Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025.
Sentiment: Positive
Publish Date: 2024-12-02 14:29:58
Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to “Attractive,” believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were strong.
Sentiment: Positive
Publish Date: 2024-11-21 09:50:37
GKOS stock gains from strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.
Sentiment: Positive
Publish Date: 2024-11-08 07:00:00
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Healthcare Conference on Tuesday, November 19, 2024, at 12:40 p.m. ET in New York City, NY Stephens Annual Investment Conference on Wednesday, Novembe.
Sentiment: Positive
Publish Date: 2024-11-05 12:31:08
The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Sentiment: Positive
Publish Date: 2024-11-05 12:21:19
Glaukos Corp GKOS reported on Monday third-quarter sales of $96.7 million, up 24% year-over-year, beating the consensus of $91.49 million.
Sentiment: Positive
Publish Date: 2024-11-05 11:01:45
Glaukos' third-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.
Sentiment: Positive
Publish Date: 2024-11-04 23:03:05
Call Start: 16:30 January 1, 0000 5:31 PM ET Glaukos Corporation. (NYSE:GKOS ) Q3 2024 Earnings Conference Call November 04, 2024, 04:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - President and COO Alex Thurman - CFO Conference Call Participants Tom Stephan - Stifel Lawrence Biegelsen - Wells Fargo Ryan Zimmerman - BTIG Matthew O'Brien - Piper Sandler Allen Gong - JPMorgan David Saxon - Needham Michael Sarcone - Jefferies Joanne Wuensch - Citigroup Steve Lichtman - Oppenheimer Anthony Petrone - Mizuho Operator Welcome to Glaukos Corporation's Third Quarter 2024 Financial Results Conference Call.
Sentiment: Negative
Publish Date: 2024-11-04 18:31:21
Glaukos (GKOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.50 per share a year ago.
Sentiment: Positive
Publish Date: 2024-10-28 11:05:36
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
